Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 7,051 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- matched Clear all
Completed Not applicable Interventional

Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study

NCT03152097
View directory record Official record
Conditions
Kidney Diseases, Cardiovascular Diseases
Interventions
Commercially available Diindolylmethane, Placebo
Dietary Supplement · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

A Novel Human Lab Model for Screening AUD Medications

NCT04249882
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Naltrexone, Varenicline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fish Oil (Omega 3), Immune Function, and Mood

NCT00385723
View directory record Official record
Conditions
Inflammation
Interventions
Omega 3 (Fish Oil) Supplementation, Placebo
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
40 Years to 88 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 2 Interventional

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Lapaquistat acetate and fenofibrate, Fenofibrate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 2 Interventional

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

NCT06152042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
North Miami Beach, Florida • Morehead City, North Carolina • Norman, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 3 Interventional

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain

NCT00869180
View directory record Official record
Conditions
Acute Pain, Ankle Sprain
Interventions
Diclofenac Sodium, Matching Placebo Patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
17 Years to 75 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Nov 9, 2026, 4:09 PM EST
Recruiting Phase 2 Interventional

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

NCT07672769
View directory record Official record
Conditions
Higher Risk Myelodysplastic Syndromes
Interventions
bexmarilimab (1mg/kg), azacitidine, Placebo, bexmarilimab (3mg/kg)
Drug
Lead sponsor
Faron Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Duarte, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

NCT03887429
View directory record Official record
Conditions
Impulse Control Disorders
Interventions
SXC-2023, Placebos
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Lincoln, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 2 Interventional Results available

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

NCT04449029
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, Placebo, Nucleos(t)ide therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Nov 9, 2026, 4:09 PM EST
Completed No phase listed Interventional Accepts healthy volunteers Results available

Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain

NCT03944629
View directory record Official record
Conditions
Arnica, Third Molar Extraction
Interventions
SinEcch, Placebo
Drug · Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 40 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

NCT01802918
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 2Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

NCT02620020
View directory record Official record
Conditions
Low Back Pain
Interventions
Fasinumab, placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
58
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Nov 9, 2026, 4:09 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs

NCT04830722
View directory record Official record
Conditions
Cellulite
Interventions
Sculptra Aesthetic
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Nov 9, 2026, 4:09 PM EST
Active, not recruiting Phase 2 Interventional

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dazucorilant 300 mg, Dazucorilant 150 mg, Placebo, Dazucorilant
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • San Francisco, California • Neptune City, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 9, 2026, 4:09 PM EST
Active, not recruiting Phase 3 Interventional

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

NCT07220759
View directory record Official record
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Cagrilintide, Placebo (matched to Cagrilintide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 3 Interventional Results available

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

NCT00498173
View directory record Official record
Conditions
Autism
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 9, 2026, 4:09 PM EST
Withdrawn Phase 4 Interventional

Cannabidiol for Treatment Resistant Depression

NCT04732169
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active study drug ( oral CBD), matching placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

NCT01232283
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast, Placebo, Topical or Phototherapy Therapy
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
19
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Nov 9, 2026, 4:09 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105
View directory record Official record
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 3 Interventional

Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo

NCT01064024
View directory record Official record
Conditions
Pain, Urinary Tract Infections
Interventions
Phenazopyridine Hydrochloride, Placebo
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Totowa, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

NCT03036124
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
86
States / cities
Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Nov 9, 2026, 4:09 PM EST
Completed Phase 4 Interventional Results available

Linagliptin as Add on to Basal Insulin in the Elderly

NCT02240680
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
60 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
38
States / cities
Sheffield, Alabama • Chula Vista, California • Costa Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Nov 9, 2026, 4:09 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
FNP-223, Placebo
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
50 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Carlsbad, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Nov 9, 2026, 4:09 PM EST
Terminated Phase 2 Interventional

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

NCT02484703
View directory record Official record
Conditions
Down Syndrome
Interventions
Placebo, RO5186582
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Nov 9, 2026, 4:09 PM EST